82 FR 18306 - Request for Information on Input on Opportunities of Engagement of External Stakeholders With the “Illuminating the Druggable Genome” (IDG) Program

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 73 (April 18, 2017)

Page Range		18306-18307
FR Document		2017-07795

NIH seeks input from the biomedical research community, biotechnology and pharmaceutical companies and other members of the public on interest and opportunities of engagement with the Illuminating the Druggable Genome (IDG) Program. The purpose of this Request for Information (RFI) is to identify and obtain comments on strategies for sharing potential data, tools, and other resources of common interest generated by the IDG Program and by external stakeholders to maximize the impact of the IDG Program.

Federal Register, Volume 82 Issue 73 (Tuesday, April 18, 2017)

[Federal Register Volume 82, Number 73 (Tuesday, April 18, 2017)]
[Notices]
[Pages 18306-18307]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-07795]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Request for Information on Input on Opportunities of Engagement 
of External Stakeholders With the ``Illuminating the Druggable Genome'' 
(IDG) Program

SUMMARY: NIH seeks input from the biomedical research community, 
biotechnology and pharmaceutical companies and other members of the 
public on interest and opportunities of engagement with the 
Illuminating the Druggable Genome (IDG) Program. The purpose of this 
Request for Information (RFI) is to identify and obtain comments on 
strategies for sharing potential data, tools, and other resources of 
common interest generated by the IDG Program and by external 
stakeholders to maximize the impact of the IDG Program.

DATES: The IDG Program Request for Information is open for public 
comment for a period of 30 days. Comments must be received by May 18, 
2017 to ensure consideration. After the public comment period has 
closed, the comments received by the IDG Program will be considered in 
a timely manner by the National Center for Advancing

[[Page 18307]]

Translational Sciences (NCATS) and the National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK).

ADDRESSES: Submissions may be sent electronically to [email protected] or by mail to Dr. Karlie Sharma, National Center for 
Advancing Translational Sciences, National Institutes of Health, 6701 
Democracy Blvd., Suite 900, Bethesda, MD 20892.

FOR FURTHER INFORMATION CONTACT: Questions about this request for 
information should be directed to Dr. Karlie Sharma, National Center 
for Advancing Translational Sciences, National Institutes of Health, 
6701 Democracy Blvd., Suite 900, Bethesda, MD 20892, [email protected], 301-451-4965.

SUPPLEMENTARY INFORMATION: Out of the nearly 30,000 genes in the human 
genome, approximately 3,000 genes are estimated to be part of the 
druggable genome--the subset of genes expressing proteins with the 
ability to bind drug-like molecules. Yet, only about ten percent of 
druggable proteins are targeted by Food and Drug Administration (FDA)-
approved drugs. Many proteins that comprise the druggable genome are 
members of the G-protein coupled receptor (GPCR), ion channel, and 
kinase families. A significant number of proteins within these classes 
are understudied and are the focus of the data and resource generation 
initiative of the IDG Program.

1. Goals and Requirements

    The IDG Program was originally funded as a three-year pilot program 
in 2014 with two overarching goals: (1) Integrate information about 
understudied druggable proteins from disparate sources into a single 
informatics site and (2) foster technology development to enable the 
determination of function and therapeutic potential of understudied 
druggable proteins. Having successfully achieved these goals, the IDG 
Program is currently transitioning to a new implementation phase 
intended to:
     Expand the informatics tools developed in the pilot phase 
to include additional data and allow users to access, analyze, and 
visualize a wide range of information on sets of proteins.
     Facilitate the elucidation of the function of understudied 
proteins from the three key druggable protein families (GPCR, ion 
channels, and kinases) by generating new reagents and new data.
     Disseminate the IDG-generated resources and data to the 
greater scientific community.

2. Information Requested

    NIH is seeking input from national and international experts and 
interested members of the public that includes, but is not limited to, 
the following areas:
     Resources that an outside organization (biotechnology or 
pharmaceutical company; non-profit organization; academic institution 
and national/international consortia) might be willing to share with 
the IDG Program and may:
[cir] Strategize development of chemical probes against proteins drawn 
from the IDG focused list
[cir] develop assays and platforms that can help to answer questions 
about understudied protein function
[cir] identify reagents that may be useful in annotation efforts
[cir] provide data or knowledge on any understudied protein
     Potential resources of the IDG Program that are of 
interest to an outside organization of the broader biomedical research 
community including:
[cir] Sharable databases of relevant subsets of data on understudied 
proteins
[cir] data analysis and query tools
[cir] links between protein target and disease pathologies
[cir] new methods of analysis to accelerate collection of data
    This RFI is for planning purposes only and should not be construed 
as a solicitation for applications or proposals, or as an obligation in 
any way on the part of the United States Federal government. The 
Federal government will not pay for the preparation of any information 
submitted or for the government's use. Additionally, the government 
cannot guarantee the confidentiality of the information provided.

    Dated: April 12, 2017.
Christopher P. Austin,
Director, NCATS.
Griffin P. Rodgers,
Director, NIDDK, Illuminating the Druggable Genome Program, National 
Center for Advancing Translational Sciences, National Institute of 
Diabetes and Digestive and Kidney Diseases.
[FR Doc. 2017-07795 Filed 4-17-17; 8:45 am]
 BILLING CODE 4140-01-P

18306 Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices

Development, 31 Center Drive, Room 2A03, Vascular Diseases Research; 93.838, Lung DEA, NIDDK, National Institutes of Health,
MSC 2425, Bethesda, MD 20892, (301) 496– Diseases Research; 93.839, Blood Diseases Room 7349, 6707 Democracy Boulevard,
0536, kaeserl@mail.nih.gov. and Resources Research, National Institutes Bethesda, MD 20892–5452, (301) 594–8894,
Any interested person may file written of Health, HHS) begumn@niddk.nih.gov.
comments with the committee by forwarding Dated: April 12, 2017. Name of Committee: National Institute of
the statement to the Contact Person listed on Michelle Trout, Diabetes and Digestive and Kidney Diseases
this notice. The statement should include the Special Emphasis Panel; NIDDK Diabetes
name, address, telephone number and when Program Analyst, Office of Federal Advisory Research Centers (P30).
applicable, the business or professional Committee Policy. Date: May 24–25, 2017.
affiliation of the interested person. [FR Doc. 2017–07740 Filed 4–17–17; 8:45 am] Time: 8:00 a.m. to 6:00 p.m.
In the interest of security, NIH has BILLING CODE 4140–01–P Agenda: To review and evaluate grant
instituted stringent procedures for entrance applications.
onto the NIH campus. All visitor vehicles, Place: DoubleTree by Hilton, Ballroom C,
including taxicabs, hotel, and airport shuttles DEPARTMENT OF HEALTH AND 8120 Wisconsin Avenue, Bethesda, MD
will be inspected before being allowed on 20814.
HUMAN SERVICES
campus. Visitors will be asked to show one Contact Person: Najma Begum, Ph.D.,
form of identification (for example, a Scientific Review Officer, Review Branch,
National Institutes of Health
government-issued photo ID, driver’s license, DEA, NIDDK, National Institutes of Health,
or passport) and to state the purpose of their Room 7349, 6707 Democracy Boulevard,
National Institute of Diabetes and Bethesda, MD 20892–5452, (301) 594–8894,
visit.
Digestive and Kidney Diseases; Notice begumm@niddk.nih.gov.
Dated: April 12, 2017. of Closed Meetings (Catalogue of Federal Domestic Assistance
Michelle Trout,
Pursuant to section 10(d) of the Program Nos. 93.847, Diabetes,
Program Analyst, Office of Federal Advisory Endocrinology and Metabolic Research;
Committee Policy. Federal Advisory Committee Act, as
93.848, Digestive Diseases and Nutrition
amended (5 U.S.C. App.), notice is
[FR Doc. 2017–07739 Filed 4–17–17; 8:45 am] Research; 93.849, Kidney Diseases, Urology
hereby given of the following meetings. and Hematology Research, National Institutes
BILLING CODE 4140–01–P
The meetings will be closed to the of Health, HHS)
public in accordance with the
provisions set forth in sections Dated: April 12, 2017.
DEPARTMENT OF HEALTH AND David Clary,
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
HUMAN SERVICES Program Analyst, Office of Federal Advisory
as amended. The grant applications and
the discussions could disclose Committee Policy.
National Institutes of Health
confidential trade secrets or commercial [FR Doc. 2017–07736 Filed 4–17–17; 8:45 am]
National Heart, Lung, and Blood property such as patentable material, BILLING CODE 4140–01–P
Institute; Notice of Closed Meeting and personal information concerning
individuals associated with the grant
Pursuant to section 10(d) of the applications, the disclosure of which DEPARTMENT OF HEALTH AND
Federal Advisory Committee Act, as would constitute a clearly unwarranted HUMAN SERVICES
amended (5 U.S.C. App.), notice is invasion of personal privacy.
hereby given of the following meeting. National Institutes of Health
The meeting will be closed to the Name of Committee: National Institute of
public in accordance with the Diabetes and Digestive and Kidney Diseases Request for Information on Input on
provisions set forth in sections Special Emphasis Panel; NIDDK Central Opportunities of Engagement of
Biorepositories Non-renewable Sample External Stakeholders With the
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Access (X01) PAR–14–301.
as amended. The grant applications and Date: May 11, 2017.
‘‘Illuminating the Druggable Genome’’
the discussions could disclose Time: 1:00 p.m. to 2:30 p.m. (IDG) Program
confidential trade secrets or commercial Agenda: To review and evaluate grant SUMMARY: NIH seeks input from the
property such as patentable material, applications. biomedical research community,
and personal information concerning Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
biotechnology and pharmaceutical
individuals associated with the grant companies and other members of the
applications, the disclosure of which Boulevard, Bethesda, MD 20892 (Telephone
Conference Call). public on interest and opportunities of
would constitute a clearly unwarranted engagement with the Illuminating the
Contact Person: Najma Begum, Ph.D.,
invasion of personal privacy. Scientific Review Officer, Review Branch, Druggable Genome (IDG) Program. The
Name of Committee: National Heart, Lung, DEA, NIDDK, National Institutes of Health, purpose of this Request for Information
and Blood Institute Special Emphasis Panel; Room 7349, 6707 Democracy Boulevard, (RFI) is to identify and obtain comments
Genetic Basis and/or Omics Phenotypes of Bethesda, MD 20892–5452, (301) 594–8894, on strategies for sharing potential data,
Heart, Lung and Blood Disorders. begumn@niddk.nih.gov. tools, and other resources of common
Date: May 12, 2017. Name of Committee: National Institute of
Time: 8:00 a.m. to 5:00 p.m.
interest generated by the IDG Program
Diabetes and Digestive and Kidney Diseases and by external stakeholders to
Agenda: To review and evaluate grant Special Emphasis Panel; PAR–16–034:
applications. NIDDK Ancillary Studies to Major Ongoing
maximize the impact of the IDG
Place: Residence Inn Bethesda, 7335 Clinical Studies (R01). Program.
Wisconsin Avenue, Bethesda, MD 20814. Date: May 15, 2017. DATES: The IDG Program Request for
Contact Person: Chang Sook Kim, Ph.D., Time: 2:00 p.m. to 4:00 p.m. Information is open for public comment
sradovich on DSK3GMQ082PROD with NOTICES

Scientific Review Officer, Office of Scientific Agenda: To review and evaluate grant
Review/DERA, National Heart, Lung, and
for a period of 30 days. Comments must
applications. be received by May 18, 2017 to ensure
Blood Institute, 6701 Rockledge Drive, Room Place: National Institutes of Health, Two
7188, Bethesda, MD 20892–7924, 301–435– Democracy Plaza, 6707 Democracy
consideration. After the public comment
0287, carolko@mail.nih.gov. Boulevard, Bethesda, MD 20892 (Telephone period has closed, the comments
(Catalogue of Federal Domestic Assistance Conference Call). received by the IDG Program will be
Program Nos. 93.233, National Center for Contact Person: Najma Begum, Ph.D., considered in a timely manner by the
Sleep Disorders Research; 93.837, Heart and Scientific Review Officer, Review Branch, National Center for Advancing

VerDate Sep<11>2014 16:55 Apr 17, 2017 Jkt 241001 PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 E:\FR\FM\18APN1.SGM 18APN1

Document Created: 2017-04-17 23:59:51
Document Modified: 2017-04-17 23:59:51

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		The IDG Program Request for Information is open for public comment for a period of 30 days. Comments must be received by May 18, 2017 to ensure consideration. After the public comment period has closed, the comments received by the IDG Program will be considered in a timely manner by the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Contact		Questions about this request for information should be directed to Dr. Karlie Sharma, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Suite 900, Bethesda, MD 20892, DK-IDG-Phase2- [email protected], 301-451-4965.
FR Citation		82 FR 18306

82 FR 18306 - Request for Information on Input on Opportunities of Engagement of External Stakeholders With the “Illuminating the Druggable Genome” (IDG) Program

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 73 (April 18, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health